Literature DB >> 16434977

Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.

J Gong1, J Zhu, O B Goodman, R G Pestell, P N Schlegel, D M Nanus, R Shen.   

Abstract

Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase (HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P<0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and PKCdelta pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCdelta inhibitors or PKCdelta siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCdelta kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCdelta signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434977     DOI: 10.1038/sj.onc.1209231

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 2.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

3.  Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity.

Authors:  Isabella Manni; Giuseppina Caretti; Simona Artuso; Aymone Gurtner; Velia Emiliozzi; Ada Sacchi; Roberto Mantovani; Giulia Piaggio
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

Review 4.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

5.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

6.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

7.  Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Authors:  Y Liu; M Karaca; Z Zhang; D Gioeli; H S Earp; Y E Whang
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

8.  Curcumin prevents and reverses murine cardiac hypertrophy.

Authors:  Hong-Liang Li; Chen Liu; Geoffrey de Couto; Maral Ouzounian; Mei Sun; Ai-Bing Wang; Yue Huang; Cheng-Wei He; Yu Shi; Xin Chen; Mai P Nghiem; Youan Liu; Manyin Chen; Fayez Dawood; Masahiro Fukuoka; Yuichiro Maekawa; Liyong Zhang; Andrew Leask; Asish K Ghosh; Lorrie A Kirshenbaum; Peter P Liu
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

9.  The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.

Authors:  Kongming Wu; Sanjay Katiyar; Agnes Witkiewicz; Anping Li; Peter McCue; Liang-Nian Song; Lifeng Tian; Ming Jin; Richard G Pestell
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 10.  Acetylation in nuclear receptor signaling and the role of sirtuins.

Authors:  Chenguang Wang; Michael J Powell; Vladimir M Popov; Richard G Pestell
Journal:  Mol Endocrinol       Date:  2007-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.